Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)

Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory... We present a case of a 23-year-old female patient with relapsed classical Hodgkin lymphoma in reduced general condition. She was refractory after multiple lines of prior chemotherapy including autologous stem cell transplantation. By applying a targeted therapy concept using brentuximab vedotin (SGN-35), the patient experienced a rapid clinical improvement with loss of B symptoms immediately after the first treatment cycle. Elevated serum levels for C-reactive protein (CRP) and lactate dehydrogenase (LDH) returned to normal, and a significant improvement of hemoglobin levels were observed. Moreover, after administration of 16 cycles, the patient remains in complete remission, lasting now for > 15 months. Tolerability of treatment was excellent without evidence of infections or peripheral neuropathy. This case illustrates the clinical potential of brentuximab vedotin in patients with end-stage Hodgkin lymphoma who would otherwise have only limited treatment options. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/durable-complete-remission-after-brentuximab-vedotin-in-a-patient-with-l90UJDOJbm
Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0078-8
Publisher site
See Article on Publisher Site

Abstract

We present a case of a 23-year-old female patient with relapsed classical Hodgkin lymphoma in reduced general condition. She was refractory after multiple lines of prior chemotherapy including autologous stem cell transplantation. By applying a targeted therapy concept using brentuximab vedotin (SGN-35), the patient experienced a rapid clinical improvement with loss of B symptoms immediately after the first treatment cycle. Elevated serum levels for C-reactive protein (CRP) and lactate dehydrogenase (LDH) returned to normal, and a significant improvement of hemoglobin levels were observed. Moreover, after administration of 16 cycles, the patient remains in complete remission, lasting now for > 15 months. Tolerability of treatment was excellent without evidence of infections or peripheral neuropathy. This case illustrates the clinical potential of brentuximab vedotin in patients with end-stage Hodgkin lymphoma who would otherwise have only limited treatment options.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Mar 29, 2013

References

  • Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
    Jona, A; Younes, A
  • Hodgkin lymphoma, version 2.2012 featured updates of the NCCN guidelines
    Hoppe, RT; Advani, RH; Ai, WZ
  • Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    Eichenauer, DA; Engert, A; Dreyling, M
  • Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
    Younes, A; Bartlett, NL; Leonard, JP
  • Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma
    Younes, A; Gopal, AK; Smith, SE
  • The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, PD; Sievers, EL
  • Brentuximab vedotin (SGN-35)
    Katz, J; Janik, JE; Younes, A
  • Paul Ehrlich’s magic bullets
    Schwartz, RS
  • Antibody-drug conjugates in cancer therapy
    Sievers, EL; Senter, PD